• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长春碱和雷帕霉素对人肝细胞癌相关血管生成的体内抑制作用

In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.

作者信息

Ribatti D, Nico B, Mangieri D, Longo V, Sansonno D, Vacca A, Dammacco F

机构信息

Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy.

出版信息

Histol Histopathol. 2007 Mar;22(3):285-9. doi: 10.14670/HH-22.285.

DOI:10.14670/HH-22.285
PMID:17163402
Abstract

This paper illustrates the use of the chick embryo chorioallantoic membrane (CAM) assay to determine the single and combined antiangiogenic effects of very low doses of vinblastine (VBL) and rapamycin (RAP) in human hepatocellular carcinoma (HCC). The angiogenic response induced by human HCC biopsy specimens was inhibited by each drug and sinergistically by their combination. Morever, immunohistochemical detection of microvessels with anti-CD31 mAB showed that their area was significantly lower in specimens treated with VBL and RAP in combination. Sinergy on the part of these well-known drugs when used in combination as antiangiogenics at very low doses may be of significance in the designing of new ways of treating HCC.

摘要

本文阐述了利用鸡胚绒毛尿囊膜(CAM)试验来测定极低剂量长春碱(VBL)和雷帕霉素(RAP)对人肝细胞癌(HCC)的单一及联合抗血管生成作用。每种药物均可抑制人肝癌活检标本诱导的血管生成反应,二者联合使用时具有协同作用。此外,用抗CD31单克隆抗体对微血管进行免疫组化检测显示,联合使用VBL和RAP处理的标本中微血管面积显著降低。这些知名药物在极低剂量联合用作抗血管生成剂时的协同作用,可能对设计治疗HCC的新方法具有重要意义。

相似文献

1
In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.长春碱和雷帕霉素对人肝细胞癌相关血管生成的体内抑制作用
Histol Histopathol. 2007 Mar;22(3):285-9. doi: 10.14670/HH-22.285.
2
Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.长春碱和雷帕霉素对人神经母细胞瘤相关血管生成的协同抑制作用。
Oncogene. 2005 Oct 13;24(45):6785-95. doi: 10.1038/sj.onc.1208829.
3
Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.悬钩子总生物碱在体内和体外均表现出抗血管生成活性。
Integr Cancer Ther. 2014 Nov;13(6):520-8. doi: 10.1177/1534735414547109. Epub 2014 Aug 22.
4
Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?低剂量节拍化疗联合顺铂:能否抑制 H22 肝癌细胞的血管生成?
Int J Exp Pathol. 2010 Feb;91(1):10-6. doi: 10.1111/j.1365-2613.2009.00684.x.
5
Natural antioxidant pedicularioside G inhibits angiogenesis and tumourigenesis in vitro and in vivo.天然抗氧化剂毛子草苷G在体内外均能抑制血管生成和肿瘤发生。
Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):30-4. doi: 10.1111/j.1742-7843.2007.00146.x. Epub 2007 Oct 31.
6
Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.沙利度胺对肝细胞癌的影响:用能量多普勒超声评估及循环血管生成因子分析
Radiology. 2005 May;235(2):509-16. doi: 10.1148/radiol.2352040271.
7
Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.癌症抗血管生成疗法的现状与展望:肝细胞癌
Int J Clin Oncol. 2006 Apr;11(2):82-9. doi: 10.1007/s10147-006-0566-5.
8
Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma.Ta1722,一种针对 VEGFR-2 的抗血管生成抑制剂,用于治疗人肝癌。
Biomed Pharmacother. 2012 Oct;66(7):499-505. doi: 10.1016/j.biopha.2012.05.002. Epub 2012 Jun 19.
9
Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.替西罗莫司/长春碱联合靶向 mTOR 和微管在肝癌中的持续抗肿瘤活性。
Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.
10
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.长春碱和雷帕霉素对人神经母细胞瘤生长、凋亡及血管生成的联合治疗效果。
Clin Cancer Res. 2007 Jul 1;13(13):3977-88. doi: 10.1158/1078-0432.CCR-06-2757.

引用本文的文献

1
Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.线粒体相关转录组特征与肝细胞癌的预后、血管侵犯、肿瘤微环境和治疗反应相关。
Oxid Med Cell Longev. 2022 Apr 30;2022:1592905. doi: 10.1155/2022/1592905. eCollection 2022.
2
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Ras/Raf/MEK/ERK和PI3K/PTEN/Akt/mTOR级联抑制剂:突变如何导致治疗耐药以及如何克服耐药
Oncotarget. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659.
3
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
肝细胞癌的靶向治疗:即将出现的新型药物。
Oncotarget. 2012 Mar;3(3):236-60. doi: 10.18632/oncotarget.466.
4
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Ras/Raf/MEK/ERK和PI3K/PTEN/Akt/mTOR抑制剂:抑制这些通路对人类健康的原理及重要性
Oncotarget. 2011 Mar;2(3):135-64. doi: 10.18632/oncotarget.240.
5
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?无毒、对财政负责、肿瘤学的未来:会始于第三世界吗?
J Pediatr Hematol Oncol. 2011 Jan;33(1):1-3. doi: 10.1097/MPH.0b013e3182024918.
6
Evolving therapies in the treatment of hepatocellular carcinoma.肝细胞癌治疗中的不断演进的疗法。
Biologics. 2008 Sep;2(3):453-62. doi: 10.2147/btt.s3254.
7
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.尽管雷帕霉素抑制宿主免疫,但它仍能延缓Wnt-1肿瘤的生长。
BMC Cancer. 2008 Jun 21;8:176. doi: 10.1186/1471-2407-8-176.
8
Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.细胞表面表达的核仁素特异性拮抗剂对肿瘤生长和血管生成的抑制作用
PLoS One. 2008 Jun 18;3(6):e2518. doi: 10.1371/journal.pone.0002518.
9
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.生长因子受体及相关信号通路作为肝细胞癌新型治疗策略的靶点
World J Gastroenterol. 2008 Jan 7;14(1):1-14. doi: 10.3748/wjg.14.1.
10
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.靶向PI3K/Akt/mTOR通路:有效联合方案及临床考量
Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50. doi: 10.1016/j.drup.2007.11.003. Epub 2007 Dec 31.